This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: The Board of Regents of the University of Nebraska. Active years: 2007.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2007
Title: Michael David Curtis: Innovator in Pharmaceutical Chemistry
Introduction
Michael David Curtis is a notable inventor based in Norwich, NY (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target alpha-2 mediated disorders.
Latest Patents
Michael holds a patent for the compound 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt, which is 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile substantially free of 2,3,7-triamino-4,6-dimethyl-1,9-phenazinedicarbonitrile. This compound, along with its anhydrous monoacetate salt, is useful in the treatment of ocular hypertension.
Career Highlights
Michael is affiliated with the University of Nebraska, where he continues to engage in research and development in the pharmaceutical sector. His work has led to advancements in treatments for various medical conditions.
Collaborations
Michael has collaborated with notable colleagues, including Jared Lynn Randall and Richard Alan Gibbs, contributing to a dynamic research environment.
Conclusion
Michael David Curtis exemplifies innovation in pharmaceutical chemistry through his patent and ongoing research efforts. His work holds promise for improving treatments for alpha-2 mediated disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile